CTOs on the Move

United Resource Networks

www.urnweb.com

 
United Resource Networks is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.urnweb.com
  • 6300 Highway 55
    Minneapolis, MN USA 55427
  • Phone: 763.797.4640

Executives

Name Title Contact Details

Similar Companies

Humedica, Inc.

Humedica, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Brighton, MA. To find more information about Humedica, Inc., please visit www.humedica.com

Vita Health Products

Vita Health Products is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kensey Nash Corporation

Kensey Nash Corporation is a medical device company known for product development and technology in the fields of resorbable biomaterials used in a variety of medical procedures and endovascular devices. The Company provides a range of products into

Sampling Technologies - STI Smart Technologies

Sampling Technologies - STI Smart Technologies is a Lower Sackville, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fresenius Kabi

Fresenius Kabi is a global health care company that specializes in lifesaving medicines and medical technologies for infusion, transfusion and clinical nutrition. Our expansive portfolio of products and global network of science and manufacturing centers provide essential support for the care of critical and chronically ill patients. We are part of Fresenius SE, a health care group with more than 100 years of experience in pharmaceuticals, medical devices and life sciences. Our employees – more than 35,000 worldwide – develop and deliver injectable pharmaceuticals and infusion systems; blood collection, transfusion and cell technologies; and essential nutrients for parenteral nutrition. We have special expertise in medicines for oncology, infection, anesthesia, analgesia and critical care. Our products are used in all sites of care – from hospitals and clinics to blood and plasma centers, and increasingly in patients’ homes. In biosimilars, we are developing products with a focus on oncology and autoimmune diseases.